PYC Therapeutics updates on dosing study of eye disease study

Latest News

PYC Therapeutics (ASX:PYC) has announced that it has completed dosing in patient cohort 4 (75 μg dose) of the ongoing Single Ascending Dose (SAD) study. 

PYC is developing first-in-class precision therapies for patients with genetic diseases for whom no treatment options are available. One of the Company’s assets is a first-in-class drug candidate currently progressing through a phase 1 clinical trial for patients with a blinding eye disease called Retinitis Pigmentosa type 11 (RP11). 

The company said it is now preparing for the initiation of an open-label Multiple Ascending Dose (MAD) study in patients with RP11.

It said the study's design has been informed by the safety profile of the investigational drug candidate established in the SAD study.

"Information from both the SAD and MAD studies (along with data from the ongoing Natural History study in RP11 patients) will inform the design of a clinical trial intended to support the registration of this drug candidate as the first treatment option for patients with this blinding eye disease," said PYC.